Online citations, reference lists, and bibliographies.
← Back to Search

FDG PET/CT Patterns Of Treatment Failure Of Malignant Pleural Mesothelioma: Relationship To Histologic Type, Treatment Algorithm, And Survival

V. Gerbaudo, M. Mamede, B. Trotman-Dickenson, H. Hatabu, D. Sugarbaker
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
PurposeThis study investigated the diagnostic performance and prognostic value of fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT in suspected malignant pleural mesothelioma (MPM) recurrence, in the context of patterns and intensity of FDG uptake, histologic type, and treatment algorithm.MethodsFifty patients with MPM underwent FDG PET/CT for restaging 11 ± 6 months after therapy. Tumor relapse was confirmed by histopathology, and by clinical evolution and subsequent imaging. Progression-free survival was defined as the time between treatment and the earliest clinical evidence of recurrence. Survival after FDG PET/CT was defined as the time between the scan and death or last follow-up. Overall survival was defined as the time between initial treatment and death or last follow-up date.ResultsTreatment failure was confirmed in 42 patients (30 epithelial and 12 non-epithelial MPM). Sensitivity, specificity, accuracy, negative predictive value, and positive predictive value for FDG PET/CT were 97.6, 75, 94, 86, and 95.3%, respectively. FDG PET/CT evidence of single site of recurrence was observed in the ipsilateral hemithorax in 18 patients (44%), contralaterally in 2 (5%), and in the abdomen in 1 patient (2%). Bilateral thoracic relapse was detected in three patients (7%). Simultaneous recurrence in the ipsilateral hemithorax and abdomen was observed in ten (24%) patients and in seven (17%) in all three cavities. Unsuspected distant metastases were detected in 11 patients (26%). Four patterns of uptake were observed in recurrent disease: focal, linear, mixed (focal/linear), and encasing, with a significant difference between the intensity of uptake in malignant lesions compared to benign post-therapeutic changes. Lesion uptake was lower in patients previously treated with more aggressive therapy and higher in intrathoracic lesions of patients with distant metastases. FDG PET/CT helped in the selection of 12 patients (29%) who benefited from additional previously unplanned treatment at the time of failure. Multivariate analysis showed that histologic type remained the only independent predictor of progression-free survival. Survival after relapse was independently predicted by the pattern of FDG uptake and PET nodal status, and overall survival by the maximum standard uptake value.ConclusionFDG PET/CT is an accurate modality to diagnose and to estimate the extent of locoregional and distant MPM recurrence, and it carries independent prognostic value. Once the disease recurs, survival outcomes seem to be independent of histologic type and highly dependent on the intensity of lesion uptake and on the pattern of metabolically active disease in FDG PET/CT. Our observations should be considered limited to patients treated surgically with or without perioperative therapies and should not be extrapolated to those unresectable cases treated with chemotherapy alone.
This paper references
10.1097/01.MNM.0000075188.60210.96
18F-FDG imaging of malignant pleural mesothelioma: scientiam impendere vero...
V. Gerbaudo (2003)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1007/BF02306613
Surgically debulked malignant pleural mesothelioma: Results and prognostic factors
H. Pass (2006)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1164/AJRCCM.149.6.7516252
In vivo measurement of neutrophil activity in experimental lung inflammation.
H. Jones (1994)
Dissociation between respiratory burst activity and deoxyglucose uptake in human neutrophil granulocytes: implications for interpretation of (18)F-FDG PET images.
H. Jones (2002)
10.1053/SNUC.2002.127291
Positron emission tomography imaging in nonmalignant thoracic disorders.
A. Alavi (2002)
10.1007/s11307-009-0203-6
Prognostic Value of 18F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1016/J.EJRAD.2007.08.010
Morphologic and functional imaging of malignant pleural mesothelioma.
M. Yamamuro (2007)
10.1016/J.THORSURG.2004.06.006
Patterns of failure following surgical resection for malignant pleural mesothelioma.
P. Jänne (2004)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
Positron emission tomography of 18FDG uptake in localized pulmonary inflammation.
H. Jones (1991)
10.1097/01.RLU.0000067521.85209.C1
Pulmonary clostridium perfringens infection detected by FDG positron emission tomography.
H. Zhuang (2003)
10.1007/BF01367602
Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients
L. Strauss (2005)
10.1053/j.semtcvs.2009.06.011
Current trends in radiologic management of malignant pleural mesothelioma.
R. Gill (2009)
10.1200/JCO.2005.04.6813
Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma.
W. Richards (2006)
10.1016/S1010-7940(00)00541-8
Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer.
M. Sonobe (2000)
10.1067/MTC.2000.106529
Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma.
D. Schneider (2000)
Role of integrated 18fluorodeoxyglucose position emission 820
C Tan (2011)
RESEARCH ARTICLE Prognostic Value of 18 F-FDG PET/CT in Patients with Malignant Pleural Mesothelioma
S. Lee (2009)
10.1097/00004728-199005000-00003
Mediastinal lymph node metastases from nonsmall cell bronchogenic carcinoma: reevaluation with CT.
J. Ikezoe (1990)
10.1097/00003072-200105000-00020
Intense F-18 fluorodeoxyglucose uptake caused by mycobacterium avium intracellulare infection.
H. Zhuang (2001)
10.1016/0169-5002(95)90602-9
Detecting recurrent or residual lung cancer with FDG-PET.
T. Inoue (1995)
10.1016/0003-4975(94)91066-9
Aggressive multimodality therapy for malignant pleural mesothelioma.
T. Rice (1994)
10.1378/CHEST.114.3.713
Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography.
F. Bénard (1998)
10.1016/J.THORSURG.2004.06.011
Epidemiology, biologic behavior, and natural history of mesothelioma.
L. Zellos (2004)
10.1097/JTO.0b013e3181cbf465
Role of Integrated 18-Fluorodeoxyglucose Position Emission Tomography-Computed Tomography in Patients Surveillance after Multimodality Therapy of Malignant Pleural Mesothelioma
C. Tan (2010)
10.1200/JCO.1994.12.6.1156
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma.
V. Rusch (1994)
10.1016/S1010-7940(00)00377-8
18-FDG positron emission tomography in the evaluation of malignant pleural diseases - a pilot study.
A. Carretta (2000)
10.1136/thorax.58.12.1077
Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma
V. Gerbaudo (2003)
10.1016/J.CTRV.2007.07.012
Assessment of tumor response in malignant pleural mesothelioma.
G. Ceresoli (2007)
10.1007/BF02303746
Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma
H. Pass (2006)
10.1016/J.JTCVS.2006.03.068
Positron emission tomography predicts survival in malignant pleural mesothelioma.
R. Flores (2006)
10.1158/1078-0432.CCR-09-2313
A Novel Prognostic Model for Malignant Mesothelioma Incorporating Quantitative FDG-PET Imaging with Clinical Parameters
A. Nowak (2010)
10.1007/s11547-006-0034-3
Imaging before and after multimodal treatment for malignant pleural mesothelioma
D. Fiore (2006)
10.1016/S0003-4975(96)01228-3
Patterns of failure after trimodality therapy for malignant pleural mesothelioma.
E. Baldini (1997)
10.1093/JNCI/DJK091
When you look matters: the effect of assessment schedule on progression-free survival.
K. Panageas (2007)
10.3109/02841869709001287
Altered fractionation of hemithorax irradiation for pleural mesothelioma and failure patterns after treatment.
L. R. Holsti (1997)
Assessment of malignant pleural mesothelioma with (18)F-FDG dual-head gamma-camera coincidence imaging: comparison with histopathology.
V. Gerbaudo (2002)



This paper is referenced by
10.5798/dicletip.705798
The Effect of Metabolic PET Parameters on Survival Outcome in Malignant Pleural Mesothelioma
N. Akdeniz (2020)
10.1183/2312508x.10032419
Radiology in pleural disease: what is the role of chest radiographs, CT and PET in modern management?
Laura Duerden (2020)
10.5152/PB.2011.08
NUCLEAR MEDICINE TECHNIQUES IN IMAGING OF PLEURAL DISEASES
Z. Celen (2011)
10.1016/j.ejrad.2016.11.009
Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma.
Shingo Kanemura (2017)
10.21608/EGYJNM.2012.5474
Role of 18F-FDG PET/CT in Malignant Pleural Mesothelioma, Initial Study
Mahasen Abo-gabal (2012)
Relationship between 18 FDG PET-CT findings and the survival of 177 patients with malignant pleural mesothelioma.
A. Abakay (2013)
10.2995/JACSURG.30.747
Lymphohistiocytoid mesothelioma of the pleura: A case report
Hideyuki Nishi (2016)
10.4274/nts.2018.008
The Role of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging in Mesothelioma
Ö. Özmen (2018)
10.1016/j.biopha.2013.01.008
¹⁸F-FDG-PET/CT in malignant mesothelioma.
C. Fuccio (2013)
10.4103/ijrc.ijrc_1_19
Pleural mesothelioma with peritoneal involvement: Diagnosed on 18F-FDG positron emission tomography/computed tomography
Anuja Anand (2019)
10.1007/s11604-016-0555-1
Present and future roles of FDG-PET/CT imaging in the management of malignant pleural mesothelioma
K. Kitajima (2016)
10.5772/31195
Monitoring of chemotherapy response in malignant pleural mesothelioma using fluorodeoxyglucose positron emission tomography.
T. Kimura (2008)
Guidelines for the Clinical Use of 18 F-FDG-PET/MRI 2012 (Ver 1.0): Part 2
U. Tateishi (2012)
10.1002/cam4.1182
Prognostic and predictive role of [18F]fluorodeoxyglucose positron emission tomography (FDG‐PET) in patients with unresectable malignant pleural mesothelioma (MPM) treated with up‐front pemetrexed‐based chemotherapy
P. Zucali (2017)
10.1016/j.cpet.2011.04.001
Multimodality Imaging Review of Malignant Pleural Mesothelioma Diagnosis and Staging.
V. Gerbaudo (2011)
10.18632/oncotarget.27324
Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT
K. Kitajima (2019)
10.1177/0300891620941610
Ovarian metastasis from malignant pleural mesothelioma.
Giuseppe Naldi (2020)
10.2214/AJR.13.10572
FDG PET/CT in the management of primary pleural tumors and pleural metastases.
Matthew J. Kruse (2013)
10.4103/0972-3919.198499
Pleuroperitoneal Mesothelioma: A Rare Entity on 18F-FDG PET/CT
M. Sahoo (2017)
10.3978/j.issn.2072-1439.2013.11.28
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.
N. van Zandwijk (2013)
10.5152/tcb.2015.060
Pet Applications For Staging And Restaging In Thoracic Malignancies
T. Ones (2015)
10.1093/ejcts/ezw045
The management of the diaphragm during radical surgery for malignant pleural mesothelioma.
A. Sharkey (2016)
10.1088/0031-9155/57/3/685
Evaluation of a method for projection-based tissue-activity estimation within small volumes of interest.
S. Southekal (2012)
Identifying response to therapy in longitudinal PET imaging studies
M. Phillips (2014)
10.1097/RLU.0b013e3182478c13
A case of primary pericardial mesothelioma detected by 18F-FDG PET/CT.
F. Aga (2012)
10.2147/LCTT.S102113
Clinical staging of malignant pleural mesothelioma: current perspectives
M. Bonomi (2017)
Clinical implications of 18 F-fluorodeoxyglucose positron emission tomography / computed tomography at delayed phase for diagnosis and prognosis of malignant pleural mesothelioma
Y. Abe (2011)
10.1007/s10147-017-1126-x
Post-recurrence chemotherapy for mesothelioma patients undergoing extrapleural pneumonectomy
T. Takuwa (2017)
10.1097/RLU.0b013e318238f6d8
Incarcerated inguinal hernia from metastatic pleural mesothelioma: PET/CT imaging.
V. X. Nguyen (2012)
10.1016/j.rmcr.2014.07.003
Multiple distant metastases in a case of malignant pleural mesothelioma
K. C. Tertemiz (2014)
10.1097/RLU.0b013e31828da61d
Multiple primary hepatic malignant mesotheliomas mimicking cystadenocarcinomas on enhanced CT and FDG PET/CT.
A. Dong (2014)
10.1016/j.clinimag.2011.03.002
PET-CT in the diagnosis of localized malignant pleural mesothelioma.
I. Dimarakis (2011)
See more
Semantic Scholar Logo Some data provided by SemanticScholar